Sun Pharma unveils Covid drug FluGuard at ₹35 a tablet

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

The stocks of the medicine will be available in the market from this week, the company said.

Sun Pharmaceutical Industries Ltd has announced the introduction of FluGuard (Favipiravir 200 mg) at a price of ₹35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India.

Glenmark’s FabiFlu is available at ₹75 a tablet as the company recently brought down the price from ₹103 a tablet during the time of introduction.

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

Kirti Ganorkar, CEO, India Business, Sun Pharma said, “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals.”

“We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response,” she said.

The company said it will work with the government and medical community to ensure availability of FluGuard to patients across the country. The stocks of the medicine will be available in the market from this week, the company added.